Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer (Q40139232)

17 September 2017

Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer (English)

1 reference

17 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

6

H Ballentine Carter

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

3

Patricia Landis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

5

Jonathan I Epstein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

Zhaoyong Feng

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Bruce J Trock

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

language of work or name

English

0 references

publication date

20 September 2013

1 reference

17 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

191

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

629-637

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

Role of active surveillance in the management of localized prostate cancer

14 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Active surveillance: the Canadian experience

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Prostate-cancer mortality at 11 years of follow-up

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

22 September 2017

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Risk stratification of men choosing surveillance for low risk prostate cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Prostate specific antigen best practice statement: 2009 update.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

The role of biopsy core number in selecting prostate cancer patients for active surveillance

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Factors predicting prostatic biopsy Gleason sum under grading.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4711358

Staging saturation biopsy in patients with prostate cancer on active surveillance protocol

2 December 2018

1 reference

12 December 2020

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

12 December 2020

Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance

1 reference

12 December 2020

Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients

1 reference

12 December 2020

Methods of calculating prostate-specific antigen velocity

1 reference

12 December 2020

Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease

1 reference

12 December 2020

10.1016/J.JURO.2013.09.029

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

release_hjmgmeryrbeghjcwdcx5ya2dbi

14 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hjmgmeryrbeghjcwdcx5ya2dbi

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060641%20AND%20SRC:MED&resulttype=core&format=json